Atul (500027) Q2 25/26 earnings summary

Executive summary

• Standalone and consolidated unaudited financial results for Q2 and H1 FY2025 were reviewed and approved by the Board on October 17, 2025, with no modifications in the auditor's limited review reports.

• Both standalone and consolidated results show year-over-year growth in revenue and profit for the six months ended September 30, 2025.

Financial highlights

• Standalone revenue from operations for Q2 FY2025 was ₹1,409.52 cr, up from ₹1,278.68 cr in Q2 FY2024; H1 FY2025 revenue was ₹2,714.08 cr, up from ₹2,486.19 cr year-over-year.

• Standalone net profit for Q2 FY2025 was ₹172.31 cr, up from ₹97.74 cr in Q2 FY2024; H1 FY2025 net profit was ₹270.05 cr, up from ₹237.93 cr year-over-year.

• Consolidated revenue from operations for Q2 FY2025 was ₹1,551.85 cr, up from ₹1,392.83 cr in Q2 FY2024; H1 FY2025 revenue was ₹3,029.85 cr, up from ₹2,714.88 cr year-over-year.

• Consolidated net profit for Q2 FY2025 was ₹182.37 cr, up from ₹132.36 cr in Q2 FY2024; H1 FY2025 net profit was ₹314.73 cr, up from ₹251.60 cr year-over-year.

• Basic and diluted EPS for H1 FY2025 were ₹91.72 (standalone) and ₹104.28 (consolidated), both higher than the previous year.

Outlook and guidance

• The company continues to focus on growth in Life Science Chemicals and Performance & Other Chemicals segments, with positive momentum in both revenue and profitability.